Novo Nordisk and Eli Lilly rival soars 32% after promising weight loss drug results
Zealand Pharma’s Phase 2 trial was an “uniquivocal win” for a drug that can treat both liver disease and obesity, analysts said. International: Top News And Analysis
News from Nashville & around the world
Zealand Pharma’s Phase 2 trial was an “uniquivocal win” for a drug that can treat both liver disease and obesity, analysts said. International: Top News And Analysis